Stock NOVA NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Novo Nordisk A/S BOERSE MUENCHEN

Equities

NOVA

US6701002056

Market Closed - BOERSE MUENCHEN
Other stock markets
 20:43:22 02/07/2024 BST 		5-day change 1st Jan Change
132.5 EUR -2.57% Intraday chart for Novo Nordisk A/S +1.13% +43.16%
07-02 Tesla, megacaps drive S&P 500, Nasdaq higher; rates outlook in focus RE
07-02 Novo Nordisk, Eli Lilly Charging 'Unconscionably' High Prices, Biden, Sanders Say MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • With an expected P/E ratio at 42.94 and 34.75 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.16% 641B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 823B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.09% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 241B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 223B
A+
NOVARTIS AG Stock Novartis AG
+13.66% 218B
B-
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.33% 160B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. NOVA Stock
  5. Ratings Novo Nordisk A/S